Suicide Warnings Have Led to Decreased Use of Antidepressants in Children
23-Nov-2010 8:00 AM EST
But Only for Non-Major Depression; More Depressed Kids Get Psychotherapy, Reports New Study in Medical Care Journal
Newswise — Philadelphia, Pa. (November 23, 2010) – An FDA warning regarding increased suicide risk in children and teens taking antidepressant drugs has led to an overall decrease in antidepressant prescribing for young patients, reports a study in the November issue of Medical Care. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.
However, the decrease appears limited to patients with less-severe depression, and has been accompanied by increased use of psychotherapy, report Satish C. Valluri, Ph.D., M.P.H., and colleagues of University of Maryland, Baltimore. Antidepressant Prescribing Decreases for Non-Major Depression…In March, 2004, the U.S. Food and Drug Administration issued a warning about a possible increase in suicidal thoughts and behavior in children and adolescents starting treatment for antidepressant drugs. Later that year, a stronger "black box" warning was added.
To analyze the impact of the warnings, the researchers analyzed rates of antidepressant prescribing for young patients with newly diagnosed depression from before to after March, 2004. The study included more than 40,000 children and adolescents diagnosed with depression from 2003 to 2006, identified from a large insurance database.
Youth diagnosed with depression after the FDA warning were 15 percent less likely to be prescribed antidepressant drugs. However, on more detailed analysis, the reduction in antidepressant use was limited to patients with diagnoses other than major depressive disorder. For this group of children with less-severe depression, antidepressant prescribing decreased by 21 percent.
In contrast, rates of antidepressant treatment were unchanged for children and adolescents with major depression. The trends in antidepressant prescribing were about the same for children (under age 12) as adolescents (aged 12 to 17).
…While More Depressed Youth Receive PsychotherapyAs antidepressant prescribing decreased, more young patients received psychotherapy after being diagnosed with depression. The increase in psychotherapy was greater for children (31 percent), but still significant for adolescents (19 percent). The difference was most pronounced for youth receiving psychotherapy as their only treatment for depression: from 37 percent before the FDA warning to 44 percent afterward.
Before and after the warning, about 80 percent of children and teens received some type of treatment—antidepressant, psychotherapy, or both—within six months after being diagnosed with depression.
Previous studies had reported decreased use of antidepressants in young patients since the 2004 FDA warnings. The new study provides a more detailed evaluation, including comparison of children versus adolescents and patients with major depressive disorder versus less-severe depression.
The results suggest that the decrease in antidepressant prescribing has been limited to patients with less severe depression—who account for the great majority of depressed youth. Meanwhile, there has been no significant change in antidepressant treatment for children and teens with major depression.
At the same time, the use of psychotherapy alone as initial treatment for depression has increased—especially among children under 12. "Together these findings suggest more clinically nuanced pediatric antidepressant prescribing patterns than previously found," Valluri and coauthors conclude. They urge further studies to evaluate the impact of reduced antidepressant prescribing in young patients with less-severe depression.
About Medical CareRated as one of the top ten journals in healthcare administration, Medical Care is devoted to all aspects of the administration and delivery of healthcare. This scholarly journal publishes original, peer-reviewed papers documenting the most current developments in the rapidly changing field of healthcare. Medical Care provides timely reports on the findings of original investigations into issues related to the research, planning, organization, financing, provision, and evaluation of health services. In addition, numerous special supplementary issues that focus on specialized topics are produced with each volume. Medical Care is the official journal of the Medical Care Section of the American Public Health Association. Visit the journal website at www.medicalcare.com.
About Lippincott Williams & Wilkins Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services.
LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health and pharmacy. Major brands include traditional publishers of medical and drug reference tools and textbooks, such as Lippincott Williams & Wilkins and Facts & Comparisons®; and electronic information providers, such as Ovid®, UpToDate®, Medi-Span® and ProVation® Medical.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer’s leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer has 2009 annual revenues of €3.4 billion ($4.8 billion), employs approximately 19,300 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.